- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04314011
Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty
A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty
The purpose of this clinical study is to answer the questions:
- Is the proposed intervention safe?
- Is the proposed intervention effective in improving the healthy status of subjects with aging frailty?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aging frailty is a clinical syndrome, characterized by a decrease of homeostatic reserves and enhanced vulnerability to endogenous or exogenous stressors, exposing individuals to an increased risk of adverse health-related outcomes. The human umbilical cord (HUC) is a promising source of mesenchymal stem cells (MSCs), compared to embryonic stem cells, HUC-MSCs are noncontroversial with a painless collection procedure and faster self-renewal properties. HUC-MSCs can differentiate into the different germ layers and modulate immune responses. One possible mechanism for the onset and development of aging frailty is the depletion of stem cells. Hence, intravenous infusion of HUC-MSCs is attractive therapy against aging frailty.
This is a randomized, double-blind, placebo-controlled clinical trial. The participants (n = 30) will be randomly distributed into two groups. The HUC-MSCs Group (n = 15) will receive intravenous infusion of mesenchymal stem cells twice over a month (30 days interval), the Control Group (n = 15) will receive the same protocolized intervention with normal saline. Follow-up duration is 6 months after first intervention. The reported serious adverse events(SAEs)will be observed within one month post infusion. The short-item from health survey(SF-36), EuroQol five dimensions questionnaire (EQ-5D) and Fried phenotype scale will be evaluated. Short physical performance battery (SPPB) and plasm biomarkers will be assessed.The assessments will be performed at baseline, 1 month, 3 months and 6 months.
The intent of this study is to explore domains of efficacy of HUC-MSCs through the reduction of signs and symptoms of aging frailty and to evaluate the safety of HUC-MSCs in subjects with aging frailty.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200120
- Shanghai East Hospital, Shanghai Tongji University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects age ≥60 and ≤80 years at the time of signing the informed consent form.
- Must show signs of frailty apart from a concomitant condition as assessed by the investigator with a frailty score of 1 to 4 using the Fried Phenotype Scale.
- Must provide written informed consent.
- Subjects are expected to live more than 12 months.
Exclusion Criteria:
- Serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study
- Advanced liver or renal failure, class III/IV congestive heart failure, myocardial infarction, unstable angina, cardiac revascularization, or severe obstructive ventilator defect.
- Uncontrolled hypertension or hyperglycemia.
- Have known allergies to biological drugs or antibiotics.
- Expecting to receive organ transplantation.
- Have a clinical history of malignancy or active autoimmune diseases.
- Have a history of drug or alcohol abuse within the past 24 months.
- Be serum-positive for HIV, hepatitis BsAg or viremic hepatitis C.
- Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
- Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HUC-MSCs Group
Human umbilical cord mesenchymal stem cells (1*10^6/kg cells): delivered via peripheral intravenous infusion.
|
Human umbilical cord mesenchymal stem cells(HUC-MSCs)
|
Placebo Comparator: Control Group
Placebo:normal saline delivered via peripheral intravenous infusion.
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of HUC-MSCs infusion
Time Frame: Within one month post infusion
|
Safety were assessed by incidence of reported serious adverse events (SAEs) within one month after infusion. An SAE is defined as any untoward medical occurrence that:
|
Within one month post infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in rate of decline of Frailty
Time Frame: Baseline, month 1, 3 month and 6 months post infusion
|
Difference in rate of decline of Frailty assessed using Fried phenotype scale:
|
Baseline, month 1, 3 month and 6 months post infusion
|
Difference in subject quality of life assessments
Time Frame: Baseline, month 1, month 3 and month 6 post infusion
|
Health-related quality of life will be assessed via Short-Form 36 Health Survey (SF-36), including physical functioning scale and mental health index; the health status including Health State Index (HSI) and respondent's self-rated health on a vertical scale will be accessed via EuroQol 5-Dimension (ED-5D).
|
Baseline, month 1, month 3 and month 6 post infusion
|
Changes in the pro-inflammatory cytokines of blood sample between the HUC-MSC and placebo cohorts
Time Frame: Baseline, month 1, month 3 and month 6 post infusion
|
Enzyme-linked immunosorbent assay will be used to identify the serum levels of pro-inflammatory cytokines (e.g.,Interleukin-6).
|
Baseline, month 1, month 3 and month 6 post infusion
|
Changes in cellular components of the immune system between the HUC-MSC and placebo cohorts
Time Frame: Baseline, month 1, month 3 and month 6 post infusion
|
Flow cytometry will be used to identify the changes in numbers of lymphocyte subpopulations (e.g., B cells, T cells).
|
Baseline, month 1, month 3 and month 6 post infusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zhongming Liu, MD/Ph.D, Shanghai East Hospital, Shanghai Tongji University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EC.D (BG).020.02.0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging Frailty
-
University of AlbertaAlberta Health services; Glenrose FoundationActive, not recruitingHealthy | Frail Elderly Syndrome | Frailty | Healthy Aging | Frailty Syndrome | Aging Problems | Aging Disorder | Pre-FrailtyCanada
-
The Opole University of TechnologyRecruitingPrevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People (FRAILPOL)Frail Elderly Syndrome | Frailty | Aging | Frailty Syndrome | Aging Problems | Fragility | Aging Well | Aging DisorderPoland
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
Cellcolabs Clinical SPV LimitedPDC-CRORecruitingAging FrailtyUnited Arab Emirates
-
University of PennsylvaniaCompleted
-
University of SouthamptonTameside Hospital NHS Foundation Trust; Bournemouth University; Southern Health...Active, not recruitingOlder People | Frailty in AgingUnited Kingdom
-
Haukeland University HospitalNot yet recruitingFrail Elderly Syndrome | Frailty | Aging | Frailty SyndromeNorway
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
Wake Forest University Health SciencesActive, not recruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States